Cosmo reports excellent preliminary unaudited Full Year 2023 core financial results Record guidance for 2024 Doubles dividend to € 2.00 per share
- Medtronic deal accounted in 2024, to inject USD 200m cash
- FDA approval of GI Genius new enhanced operating system
- New GI drug development program announced
- Outlook for 2025
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its preliminary unaudited results for the financial year 2023.